Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
DYAI Stock Summary
Top 10 Correlated ETFs
DYAI
In the News

Dyadic International, Inc. (DYAI) Q3 2023 Earnings Call Transcript
Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Emalfarb - President, Chief Executive Officer Ping Rawson - Chief Financial Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Paul Rosenbaum - SWR Operator Good evening, and welcome to the Dyadic International's Third Quarter 2023 Financial Results Conference Call. Currently all participants are in a listen-only mode.

Dyadic to Present at Industry Events in November
JUPITER, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participating and presenting at the following industry events during the month of November: Cultured Meat Symposium 2023, November 2-3, 2023StarBase, Las VegasJoseph Hazelton, Chief Business Officer 8th International Vaccines Research & Development, November 6-8, 2023Hilton Baltimore BWI Airport Hotel, Linthicum Heights, MDMark Emalfarb, President, and Chief Executive Officer “Next-Gen Vaccines without the Right Platform Limit Pandemic Effectiveness C1, Protective, Rapid, High Yield, Low-Cost Global Solution” Presentation Time: Monday, November 6, 2023, 2:10 PM – 2:30 PM ET BARDA Industry Day 2023, November 13-14, 2023Grand Hyatt Washington, Washington, DCJoseph Hazelton, Chief Business Officer Vaccines Summit, November 13-15, 2023Sheraton Boston Needham Hotel, Boston, MAMark Emalfarb, President, and Chief Executive Officer “Rapid development and flexible scale of complex recombinant proteins and antigens including ferritin nanoparticles for infectious diseases including COVID-19 and seasonal and pandemic influenza” Presentation Time: Wednesday, November 15, 2023, 1:40 PM – 2:00 PM ET If you would like to connect with Dyadic's management at any of these events, you may request a one-on-one meeting at jlavalley@dyadic.com About Dyadic International, Inc. Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health.

Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the third quarter 2023 and host a corporate update conference call on Wednesday, November 8, 2023.

Dyadic to Present at Industry and Investor Events in October
JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be presenting at the following industry and investor events during the month of October: Enzyme Engineering XXVII, October 1-6, 2023Park Royal Hotel, SingaporeDr. Ronen Tchelet, Chief Scientific Officer “The use of in silico analysis to engineer the best immunogenic epitope and produce the corresponding prophylactic antigen-based vaccines with C1 production platform in order to rapidly respond to viral pandemics” Wednesday, October 4, 2023, 11:00 AM – 11:30 AM LD Mirco Main Event XVI, October 3-5, 2023Luxe Sunset Blvd Hotel, Los Angeles, CAMark Emalfarb, President, and Chief Executive Officer “Next Generation Proteins for World Health, Nutrition and Wellness” Wednesday, October 4, 2023, 8:00 AM – 8:25 AM World Vaccine Congress Europe, October 16-19, 2023Fira de Barcelona Montjuic, Barcelona, SpainMark Emalfarb, President, and Chief Executive Officer “Rapid development and flexible scale manufacturing of complex recombinant proteins and antigens including ferritin nanoparticles for seasonal and pandemic influenza vaccines” Wednesday, October 18, 2023, 11:45 AM – 12:00 PM If you would like to connect with Dyadic's management at any of the events, you may request a one-on-one meeting at jlavalley@dyadic.com.

Dyadic to Present at BioProcess International
JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.

Dyadic International, Inc. (DYAI) Q2 2023 Earnings Call Transcript
Dyadic International, Inc. (NASDAQ:DYAI ) Q2 2023 Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Dick Williams - Williams Research Group Robert Smith - Center for Performance Investing Tony Bowers - Intro Act Operator Good evening, and welcome to Dyadic International's Second Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
JUPITER, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the second quarter 2023 and host a corporate update conference call on Wednesday, August 9, 2023.

Dyadic International, Inc. (DYAI) Q1 2023 Earnings Call Transcript
Dyadic International, Inc. (NASDAQ:DYAI ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Operator Good evening, and welcome to Dyadic International's First Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it will report its financial results for first quarter 2023 and host a corporate update conference call on Wednesday, May 10, 2023.

Dyadic reports 21.9% revenue rise, $12.7M in cash for full year 2022 as it rapidly advances technology
Dyadic International Inc (NASDAQ:DYAI) posted its financial results for the year ended 2022 with revenue surging 21.9% year-over-year on the back of license agreements as it rapidly advanced its technology. For the year ended December 31, 2022, the Jupiter, Florida-based biotechnology platform company reported research and development (R&D) revenue of $2.93 million, compared to $2.40 million for the year ended December 31, 2021.
DYAI Financial details
DYAI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.05 | 0.06 | 0.06 | 0.09 | 0.1 | |
Net income per share | -0.21 | -0.31 | -0.34 | -0.46 | -0.33 | |
Operating cash flow per share | -0.16 | -0.21 | -0.24 | -0.41 | -0.28 | |
Free cash flow per share | -0.16 | -0.21 | -0.24 | -0.41 | -0.28 | |
Cash per share | 1.49 | 1.27 | 1.06 | 0.73 | 0.45 | |
Book value per share | 1.53 | 1.33 | 1.04 | 0.66 | 0.39 | |
Tangible book value per share | 1.53 | 1.33 | 1.04 | 0.66 | 0.39 | |
Share holders equity per share | 1.53 | 1.33 | 1.04 | 0.66 | 0.39 | |
Interest debt per share | 0.03 | 0 | 0 | 0 | -0.01 | |
Market cap | 52.3M | 139.88M | 147.8M | 125.83M | 34.89M | |
Enterprise value | 49.92M | 135.06M | 127.16M | 110.08M | 29.09M | |
P/E ratio | -9.19 | -16.84 | -15.85 | -9.74 | -3.72 | |
Price to sales ratio | 40.37 | 83.21 | 92.26 | 52.34 | 11.91 | |
POCF ratio | -11.87 | -24.19 | -22.48 | -11.16 | -4.32 | |
PFCF ratio | -11.87 | -24.19 | -22.48 | -11.16 | -4.32 | |
P/B Ratio | 1.23 | 3.9 | 5.2 | 6.84 | 3.15 | |
PTB ratio | 1.23 | 3.9 | 5.2 | 6.84 | 3.15 | |
EV to sales | 38.53 | 80.34 | 79.38 | 45.79 | 9.93 | |
Enterprise value over EBITDA | -6.61 | -14.64 | -12.48 | -6.82 | -2.89 | |
EV to operating cash flow | -11.33 | -23.35 | -19.34 | -9.76 | -3.6 | |
EV to free cash flow | -11.33 | -23.35 | -19.34 | -9.76 | -3.6 | |
Earnings yield | -0.11 | -0.06 | -0.06 | -0.1 | -0.27 | |
Free cash flow yield | -0.08 | -0.04 | -0.04 | -0.09 | -0.23 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 0.32 | 0.52 | 2.03 | 0.98 | 0.58 | |
Current ratio | 50.31 | 22.44 | 18.32 | 8.22 | 5.48 | |
Interest coverage | -8.49 | 0 | 0 | 0 | 26.59 | |
Income quality | 0.77 | 0.7 | 0.71 | 0.86 | 0.83 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.49 | 3.28 | 3.8 | 2.79 | 2.19 | |
Research and developement to revenue | 2.56 | 2.35 | 2.41 | 3.49 | 1.54 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0.36 | 0.7 | 1.03 | 0.74 | 0.64 | |
Graham number | 2.66 | 3.03 | 2.81 | 2.63 | 1.7 | |
ROIC | -0.15 | -0.26 | -0.35 | -0.79 | -0.88 | |
Return on tangible assets | -0.13 | -0.22 | -0.31 | -0.61 | -0.68 | |
Graham Net | 1.49 | 1.24 | 1.01 | 0.63 | 0.36 | |
Working capital | 41.9M | 34.05M | 28.16M | 18.45M | 10.97M | |
Tangible asset value | 42.45M | 35.86M | 28.45M | 18.39M | 11.09M | |
Net current asset value | 41.9M | 34.05M | 28.16M | 18.1M | 10.8M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 940.36K | 1.13M | 772.5K | 389.33K | 380.25K | |
Average payables | 414.66K | 626.22K | 978.24K | 1.28M | 1.41M | |
Average inventory | 634.32K | 126.72K | 0 | 0 | 0 | |
Days sales outstanding | 315.52 | 247.2 | 92.61 | 56.52 | 48.37 | |
Days payables outstanding | 109.81 | 235.89 | 259.51 | 290.57 | 219.41 | |
Days of inventory on hand | 90.05 | 0 | 0 | 0 | 0 | |
Receivables turnover | 1.16 | 1.48 | 3.94 | 6.46 | 7.55 | |
Payables turnover | 3.32 | 1.55 | 1.41 | 1.26 | 1.66 | |
Inventory turnover | 4.05 | 0 | 0 | 0 | 0 | |
ROE | -0.13 | -0.23 | -0.33 | -0.7 | -0.85 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.03 | 0.03 | 0.03 | 0.03 | 0.01 | |
Net income per share | -0.06 | -0.07 | 0 | -0.07 | -0.06 | |
Operating cash flow per share | -0.06 | -0.06 | -0.08 | -0.06 | -0.07 | |
Free cash flow per share | -0.06 | -0.06 | -0.08 | -0.06 | -0.07 | |
Cash per share | 0.5 | 0.45 | 0.41 | 0.35 | 0.28 | |
Book value per share | 0.44 | 0.39 | 0.38 | 0.31 | 0.27 | |
Tangible book value per share | 0.44 | 0.39 | 0.38 | 0.31 | 0.27 | |
Share holders equity per share | 0.44 | 0.39 | 0.38 | 0.31 | 0.27 | |
Interest debt per share | 0 | 0 | -0.04 | 0 | 0.01 | |
Market cap | 54.23M | 34.89M | 51.2M | 55.61M | 55.32M | |
Enterprise value | 47.49M | 29.09M | 44.82M | 49.76M | 48.06M | |
P/E ratio | -7.97 | -4.21 | 93.01 | -6.46 | -8.57 | |
Price to sales ratio | 61.65 | 46.91 | 52.34 | 66.42 | 139.32 | |
POCF ratio | -30.53 | -20.75 | -23.41 | -33.6 | -28.2 | |
PFCF ratio | -30.53 | -20.75 | -23.41 | -33.6 | -28.2 | |
P/B Ratio | 4.3 | 3.15 | 4.74 | 6.19 | 7.23 | |
PTB ratio | 4.3 | 3.15 | 4.74 | 6.19 | 7.23 | |
EV to sales | 53.99 | 39.12 | 45.83 | 59.44 | 121.05 | |
Enterprise value over EBITDA | -25.85 | -13.3 | -22.1 | -22.01 | -28.36 | |
EV to operating cash flow | -26.74 | -17.3 | -20.5 | -30.07 | -24.5 | |
EV to free cash flow | -26.74 | -17.3 | -20.5 | -30.07 | -24.5 | |
Earnings yield | -0.03 | -0.06 | 0 | -0.04 | -0.03 | |
Free cash flow yield | -0.03 | -0.05 | -0.04 | -0.03 | -0.04 | |
Debt to equity | 0 | 0 | 0 | 0 | 0.02 | |
Debt to assets | 0 | 0 | 0 | 0 | 0.02 | |
Net debt to EBITDA | 3.67 | 2.65 | 3.14 | 2.58 | 4.28 | |
Current ratio | 6.25 | 5.48 | 6.83 | 5.53 | 6.24 | |
Interest coverage | -34.32 | 33.13 | 1.87 | 0 | 0 | |
Income quality | 0.98 | 0.78 | 2.29 | 0.77 | 1.22 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.57 | 2.24 | 1.51 | 1.68 | 3.23 | |
Research and developement to revenue | 0.85 | 0.79 | 0.83 | 1.1 | 1.8 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0.57 | 0.65 | 0.34 | 0.4 | 0.71 | |
Graham number | 0.77 | 0.8 | 0.2 | 0.72 | 0.58 | |
ROIC | -0.14 | -0.19 | 0.03 | -0.24 | -0.2 | |
Return on tangible assets | -0.11 | -0.15 | 0.01 | -0.19 | -0.17 | |
Graham Net | 0.42 | 0.36 | 0.36 | 0.3 | 0.24 | |
Working capital | 12.54M | 10.97M | 10.93M | 9.07M | 7.63M | |
Tangible asset value | 12.61M | 11.09M | 10.8M | 8.99M | 7.65M | |
Net current asset value | 12.32M | 10.8M | 10.8M | 8.98M | 7.48M | |
Invested capital | 0 | 0 | 0 | 0 | 0.02 | |
Average receivables | 733.46K | 333.76K | 586.23K | 793.91K | 615.68K | |
Average payables | 936.22K | 1.03M | 1.02M | 838.12K | 753.01K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 28.57 | 46.99 | 72.16 | 86.4 | 96.95 | |
Days payables outstanding | 116.04 | 163.05 | 95.38 | 102.82 | 510.19 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 3.15 | 1.92 | 1.25 | 1.04 | 0.93 | |
Payables turnover | 0.78 | 0.55 | 0.94 | 0.88 | 0.18 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.13 | -0.19 | 0.01 | -0.24 | -0.21 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
DYAI Frequently Asked Questions
What is Dyadic International, Inc. stock symbol ?
Dyadic International, Inc. is a US stock , located in Jupiter of Fl and trading under the symbol DYAI
What is Dyadic International, Inc. stock quote today ?
Dyadic International, Inc. stock price is $1.77 today.
Is Dyadic International, Inc. stock public?
Yes, Dyadic International, Inc. is a publicly traded company.